Lonza Signs Agreement With NextPharma to Sell Two Sites
By Olivia Bugault
Swiss life-sciences company Lonza Group AG has signed an
agreement for the potential sale of two sites to NextPharma, one in
Ploermel, France, and another in Edinburgh, Scotland, the two
companies said jointly on Tuesday.
The two sites, which are specialized in lipid oral dosage forms
and employ a total of 390 workers, will allow the contract
development and manufacturing organization NextPharma to develop
its technology offering in this field, the companies said.
"With this intended divestment, Lonza plans to exit both
softgels and liquid-filled hard capsules for the pharma market,
aside from retaining capability for feasibility studies as part of
a technology selection offering," they said.
The agreement is subject to regulatory approvals, the companies
Write to Olivia Bugault at email@example.com
(END) Dow Jones Newswires
January 19, 2021 01:51 ET (06:51 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.